Basit öğe kaydını göster

dc.contributor.authorAksan, Gokhan
dc.contributor.authorSoylu, Korhan
dc.contributor.authorDemircan, Sabri
dc.contributor.authorAksoy, Olcay
dc.contributor.authorYanik, Ahmet
dc.contributor.authorGedikli, Omer
dc.contributor.authorYilmaz, Ozcan
dc.date.accessioned2020-06-21T13:52:56Z
dc.date.available2020-06-21T13:52:56Z
dc.date.issued2014
dc.identifier.issn0957-5235
dc.identifier.issn1473-5733
dc.identifier.urihttps://doi.org/10.1097/MBC.0000000000000127
dc.identifier.urihttps://hdl.handle.net/20.500.12712/14941
dc.descriptionWOS: 000343097300008en_US
dc.descriptionPubMed: 24721807en_US
dc.description.abstractThe data on the successful use of oral anticoagulation (OAC) in patients with atrial fibrillation are inconclusive. We aimed to describe the indications and the utilization patterns of OAC therapy in patients with atrial fibrillation who have been admitted to a quaternary hospital. Patients who were admitted to a quaternary hospital from January 2011 to January 2012 with atrial fibrillation were included in the study. The data on patient demographics, atrial fibrillation classification, CHA2DS2VASc scores, and the use of OAC were collected. Of the patients admitted, 301 patients met the inclusion criteria. Of these, 277 (92%) had a CHA2DS2VASc score at least 2. Of the patients who met criteria for treatment with OAC, 104 (36.6%) were not on OAC therapy. The reason for this discrepancy was tendency and history of bleeding (29.8%). Of those 180 patients who were on OAC, the time in therapeutic range was higher in those patients less than 50 years as compared with those between ages 65-74 and more than 75 (78.2 versus 42 and 36.1%, P<0.05). The overall time in therapeutic range of patients on OAC was 47.4%. We found that approximately one-third of the patients who have indications for OAC are not being treated as per guidelines due to history of and tendency for bleeding. Furthermore, of those on OAC, only half of the patients achieved successful anticoagulation. Blood Coagul Fibrinolysis 25:688-694 2014 (C) Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.en_US
dc.language.isoengen_US
dc.publisherLippincott Williams & Wilkinsen_US
dc.relation.isversionof10.1097/MBC.0000000000000127en_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectanticoagulationen_US
dc.subjectatrial fibrillationen_US
dc.subjectwarfarinen_US
dc.titleOral anticoagulant therapy and clinical outcomes in patients with atrial fibrillation: a pilot study from a single center registryen_US
dc.typearticleen_US
dc.contributor.departmentOMÜen_US
dc.identifier.volume25en_US
dc.identifier.issue7en_US
dc.identifier.startpage688en_US
dc.identifier.endpage694en_US
dc.relation.journalBlood Coagulation & Fibrinolysisen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster